低血清miR-373预示胰腺癌患者预后不良。

Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.

作者信息

Hua Yongqiang, Chen Hao, Wang Libing, Wang Feng, Wang Peng, Ning Zhouyu, Li Ye, Liu Luming, Chen Zhen, Meng Zhiqiang

机构信息

Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Cancer Biomark. 2017 Jul 19;20(1):95-100. doi: 10.3233/CBM-170231.

DOI:10.3233/CBM-170231

PMID:28759959

Abstract

BACKGROUND

Circulating microRNAs (miRNAs) are emerging as novel biomarkers for various types of cancer including pancreatic cancer (PC).

OBJECTIVE

We aimed to explore the diagnostic and prognostic significance of serum miR-373 in PC.

METHODS

In the current study, we recruited a total of 103 PC patients, 30 patients with benign pancreatic tumor, 20 patients with chronic pancreatitis and 50 healthy volunteers. Total RNA was isolated from all the blood samples, and relative miR-373 expression levels were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

RESULTS

Our findings demonstrated that serum miR-373 expression was greatly down-regulated in PC patients. The area under the receiver-operating characteristic (ROC) curve (AUC) for serum miR-373 was 0.852 for discriminating PC patients from normal control subjects. In addition, a positive correlation was observed between reduced serum miR-373 level and several clinical parameters, including TNM stage, lymph node metastasis and distant metastasis. Moreover, PC patients with lower serum miR-373 level had shorter 5 year overall survival. Finally, serum miR-373 was proved to be an independent predictor for PC.

CONCLUSIONS

Taken together, serum miR-373 might serve as a promising biomarker for the early detection and prognosis prediction of PC.

摘要

背景

循环微小RNA（miRNA）正成为包括胰腺癌（PC）在内的各种癌症的新型生物标志物。

目的

我们旨在探讨血清miR-373在胰腺癌中的诊断和预后意义。

方法

在本研究中，我们共招募了103例胰腺癌患者、30例胰腺良性肿瘤患者、20例慢性胰腺炎患者和50名健康志愿者。从所有血液样本中分离总RNA，并通过逆转录定量聚合酶链反应（RT-qPCR）检测相对miR-373表达水平。

结果

我们的研究结果表明，胰腺癌患者血清miR-373表达显著下调。血清miR-373用于区分胰腺癌患者与正常对照受试者的受试者操作特征（ROC）曲线下面积（AUC）为0.852。此外，血清miR-373水平降低与包括TNM分期、淋巴结转移和远处转移在内的几个临床参数之间存在正相关。此外，血清miR-373水平较低的胰腺癌患者5年总生存期较短。最后，血清miR-373被证明是胰腺癌的独立预测指标。